StreetInsider.com News Articles

Liminatus Pharma amends merger deal with InnocsAI, closing set July 2

Tue, 30 Jun 2026 16:30:13 -0400

Liminatus Pharma, Inc. (Nasdaq: LIMN) has amended its definitive merger agreement with InnocsAI LLC, restructuring the transaction to allow closing before obtaining stockholder approval, according to a press release from the company.

The closing is now expected to occur on July 2, 2026, subject to customary closing conditions. The deal carries an aggregate implied transaction value of approximately $320 million.

Under the amended terms, InnocsAI equity holders will receive a combination of Liminatus common stock and newly designated non-voting convertible preferred stock, priced at $0.20 per common share. Equity holders will also receive contingent value rights entitling them to 20% of future

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Tue, 30 Jun 2026 16:30:00 -0400

Transaction Expected to Close July 2, 2026

FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology company focused on next-generation cell therapy technologies.

The transaction has been re-structured to allow closing prior to obtaining stockholder approval, with closing now expected to occur on July 2, 2026, subject to the satisfaction or waiver of customary closing conditions.

Under the amended terms of

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

Tue, 30 Jun 2026 16:30:00 -0400

Transaction Expected to Close July 2, 2026

Under the amended terms of

Form PRE 14A Liminatus Pharma, Inc. For: Jun 29

Tue, 30 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260630/26708941.html

Form PRE 14A Liminatus Pharma, Inc. For: Jun 29

Tue, 30 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260630/26708941.html

Liminatus Pharma (LIMN) files for 20.7M share offering by selling stockholders

Wed, 24 Jun 2026 06:07:33 -0400

Liminatus Pharma (NASDAQ: LIMN) has filed for up to 20,688,000 share offering by selling stockholders.

Liminatus Pharma (LIMN) files for 20.7M share offering by selling stockholders

Wed, 24 Jun 2026 06:07:33 -0400

Liminatus Pharma (NASDAQ: LIMN) has filed for up to 20,688,000 share offering by selling stockholders.

Form S-1 Liminatus Pharma, Inc.

Wed, 24 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260624/26681721.html

Form S-1 Liminatus Pharma, Inc.

Wed, 24 Jun 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260624/26681721.html

Form D Liminatus Pharma, Inc.

Thu, 18 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260618/26666225.html

Form D Liminatus Pharma, Inc.

Thu, 18 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260618/26666225.html

Form 8-K Liminatus Pharma, Inc. For: Jun 03

Wed, 03 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260603/26600261.html

Form 8-K Liminatus Pharma, Inc. For: Jun 03

Wed, 03 Jun 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260603/26600261.html

Form 424B3 Liminatus Pharma, Inc.

Wed, 03 Jun 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260603/26596033.html

Form 424B3 Liminatus Pharma, Inc.

Wed, 03 Jun 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260603/26596033.html

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Wed, 03 Jun 2026 08:30:00 -0400

FULLERTON, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10,344,000 shares of common stock of the Company (the “Existing Warrants”). In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the “New Warrants”). In connection with the exercise, the Company also agreed to reduce the exercise

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Wed, 03 Jun 2026 08:30:00 -0400

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Wed, 03 Jun 2026 08:30:00 -0400

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

Wed, 03 Jun 2026 08:30:00 -0400

Form 8-K Liminatus Pharma, Inc. For: May 20

Wed, 27 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260527/26558422.html

Form 8-K Liminatus Pharma, Inc. For: May 20

Wed, 27 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260527/26558422.html

Liminatus Pharma receives NASDAQ delisting notice, plans appeal

Thu, 21 May 2026 20:28:36 -0400

Liminatus Pharma, Inc. (NASDAQ: LIMN) received a delisting notice from NASDAQ after failing to meet market value requirements for continued listing, according to a company statement.

The biopharmaceutical company did not regain compliance with NASDAQ's $50 million market value of listed securities requirement and $15 million market value of publicly held shares requirement by the May 18, 2026 deadline. NASDAQ initially notified the company of the deficiency on November 19, 2025, providing a 180-day compliance period.

NASDAQ issued the delisting determination on May 20, 2026. Trading of the company's common stock and warrants will be suspended at the opening of business on

Liminatus Pharma receives NASDAQ delisting notice, plans appeal

Thu, 21 May 2026 20:28:36 -0400

Liminatus Pharma, Inc. (NASDAQ: LIMN) received a delisting notice from NASDAQ after failing to meet market value requirements for continued listing, according to a company statement.

NASDAQ issued the delisting determination on May 20, 2026. Trading of the company's common stock and warrants will be suspended at the opening of business on

Liminatus Pharma receives NASDAQ delisting notice, plans appeal

Thu, 21 May 2026 20:28:36 -0400

Liminatus Pharma, Inc. (NASDAQ: LIMN) received a delisting notice from NASDAQ after failing to meet market value requirements for continued listing, according to a company statement.

NASDAQ issued the delisting determination on May 20, 2026. Trading of the company's common stock and warrants will be suspended at the opening of business on

Liminatus Pharma receives NASDAQ delisting notice, plans appeal

Thu, 21 May 2026 20:28:36 -0400

Liminatus Pharma, Inc. (NASDAQ: LIMN) received a delisting notice from NASDAQ after failing to meet market value requirements for continued listing, according to a company statement.

NASDAQ issued the delisting determination on May 20, 2026. Trading of the company's common stock and warrants will be suspended at the opening of business on